(Reuters) – Europe’s medicines regulator said on Tuesday it has started a real-time review of Sinovac’s COVID-19 vaccine, based on preliminary results from animal and human trials that suggested the vaccine produces an immune response against the coronavirus.
Data on the vaccine, COVID-19 Vaccine (Vero Cell) Inactivated, will be assessed as they are made available to help speed-up potential approvals, the European Medicines Agency said.
(Reporting by Pushkala Aripaka in Bengaluru, Editing by Sherry Jacob-Phillips)
